21 / 25
Page 74
conferenceseries
.com
Volume 8, Issue 3(Suppl)
J Allergy Ther, an open access journal
ISSN: 2155-6121
Allergy-Clinical Immunology 2017
September 07-08, 2017
September 07-08, 2017 | Edinburgh, Scotland
ALLERGY, ASTHMA & CLINICAL IMMUNOLOGY
11
th
International Conference on
HAGE-derived vaccines for the treatment of patients with TNBC patients that are predicted to have
high risk of relapsed and poor survival rate, as assessed by a newly identified immune-gene signature
Stephanie E McArdle
1
, Divya Nagarajan
1
, Gemma Foulds
1
, Lindy Durrant
2
, Dennis Christensen
3
, Stephen Y T Chan
4
, Sergio Rutella
1
and
A Graham
Pockley
1
1
The John van Geest Cancer Research Centre, Nottingham Trent University, Clifton campus, Nottingham, NG11 8NS
2
Clinical Oncology, Nottingham City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK.
3
Statens Serum Institut, 5 Artillerivej, DK-2300 Copenhagen S, Denmark.
4
Clinical Oncology Department, Nottingham University Hospitals, Nottingham NG5 1PB, UK
T
riple Negative Breast Cancer (TNBC) consists of very heterogeneous subgroups of breast cancers with significant clinical
challenge, the prognosis and treatment of which remains poor and limited due to the lack of targeting structures for existing
therapies. We hypothesised that disease recurrence and therapeutic resistance in those patients could be influenced/predicted
by tumour-related immune-regulatory events that are reflected by changes in the immune phenotypes in the periphery. It is
conceivable that the analysis of immune gene transcripts in the blood will inform clinical decisions and help predict which
patients are likely to respond/benefit from chemo- and/or immune-therapy. Although, breast cancer has not traditionally
been viewed as being particularly susceptible to immunotherapeutic approaches, recent evidence has demonstrated a role
for immune surveillance in determining patient outcome. Moreover, recent data suggest that some patients with TNBC may
benefit from immune-stimulating therapies that may act synergistically when combined with chemotherapeutic drugs and
tumour vaccines targeting cancer specific antigens (CSAs) expressed in TNBC. We have found that the cancer testis antigen
HAGE (DDX43, CT13) is expressed in 43% of patients with TNBC. In this study, we have assessed the potential value of a newly
identified HAGE-derived vaccine, as administered using two different delivery systems, for the treatment of TNBC patients
using pre-clinical models. We have also used the nanoString nCounter™ FLEX amplification-free gene profiling platform to
determine whether the immune-related-gene profiles in the PBMC of TNBC patients could predict patients with high risk
of recurrence and poor survival rate. We therefore propose that TNBC patients with such a gene profile may benefit from a
HAGE-derived vaccine.
J Allergy Ther 2017, 8:3(Suppl)
DOI: 10.4172/2155-6121-C1-006